Fig. 6.

Comparison of antibody avidity in individuals previously infected compared with those who were vaccinated with the mRNA-1273 vaccine. Sera of 10 individuals, collected approximately 1 month (25–28 days after vaccination; median: 28 days) after their first dose of the mRNA-1273 vaccine, were analyzed for antibody avidity. These results were compared with those of the 20 individuals in the previously described COVID-19–positive cohort that had specimens collected approximately 1 month after infection (21–30 days after symptom onset; median: 26 days). For further comparison, the antibody avidity at approximately 6 months after infection in these 20 individuals who were COVID-19 positive were also displayed (165–204 days after vaccination; median: 183 days).